Giant cell tumour of the bone treated with denosumab: How has the blood supply and oncological prognosis of the tumour changed?

• DOI: 10.1016/j.jot.2018.10.003
• Publication Date: 2018-11-07T12:52:26Z
• Authors: Xiaohui Niu; Yongkun Yang; Kwok Chuen Wong; Zhen Huang; Yi Ding; Wen Zhang
• Keywords: Denosumab; Blood supply; Refractory (planetary science)

Denosumab is gradually applied to refractory or unresectable giant cell tumour of the bone. Whether denosumab can effectively reduce blood supply and bring benefit worthy study. The aim study evaluate related changes after treatment: supply, surgical plan downstaging, difficulty oncological prognosis.A self-case-control was performed from June 2014 November 2016, 18 patients were enrolled. Patients received subcutaneous 120 mg every 4 weeks preoperatively, with additional doses administered on Days 8 15 during first month therapy. initial treatment duration 12 weeks. After treatment, enhanced CT examination for evaluating whether practicable. preoperative 5 (median 3, range 3-12) months in average. microvessel density samples calculated supply. computed tomography (CT) enhancement rate compared before treatment. parameters recorded as following: clinical benefits, serious side effects, CT, plans, intraoperative loss, operative time, difficulty, histological local recurrence. followed up 3 postoperatively.The average lesions 2.08 1.40 (p = 0.000), respectively. unenhanced value significantly increased 0.038). changed more pelvic sacral than that limb 0.024). Sixteen cases underwent final surgery, downstaged. showed cells reduced even disappeared decreased mean postoperative follow-up 18.8 (10-31) months, five had high recurrence (4/6) tumours may be curettage.Denosumab tumour. lesions. downstaging also achieved. clear margin facilitated resection but, difficult curettage being concerned.Denosumab a new type humanized monoclonal antibody which some effect tumor Pre-operative denosamub intra-operative loss down-stage suitable cases.